Trial Profile
Effects of ROSIglitazone on inflammatory markers and adipokines in diabetic patients using an angiotensin receptor blocker (TELmisartan) - the ROSITEL study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ROSITEL
- 24 Nov 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 24 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2007 New trial record.